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AbstrAct
The increasing complexity of the genetic landscape in 
amyotrophic lateral sclerosis (ALS) and frontotemporal 
dementia (FTD) presents a significant resource and 
physician training challenge. At least 10% of those 
diagnosed with ALS or FTD are known to carry an 
autosomal dominant genetic mutation. There is no 
consensus on what constitutes a positive family history, 
and ascertainment is unreliable for many reasons. 
However, symptomatic individuals often wish to 
understand as much as possible about the cause of their 
disease, and to share this knowledge with their family. 
While the right of an individual not to know is a key 
aspect of patient autonomy, and despite the absence 
of definitive therapy, many newly diagnosed individuals 
are likely to elect for genetic testing if offered. It is 
incumbent on the practitioner to ensure that they are 
adequately informed, counselled and supported in this 
decision.
IntroductIon
High on the list of questions for those diagnosed 
with amyotrophic lateral sclerosis (ALS), frontotem-
poral dementia (FTD) and other neurodegenerative 
disorders is whether the disease is hereditary. It may 
be easy for the clinician to overlook the strength 
of an individual’s desire to understand the factors 
leading to their disease, including genetic causes, 
even if this does not change specific treatment. If no 
relevant family history is revealed by a newly diag-
nosed individual with ALS where good knowledge 
of the family exists, one study has suggested that 
their children have almost the same chance of not 
developing ALS as the general population.1 In the 
context of conveying the news of a terminal diag-
nosis, the desire to offer some aspect of reassurance 
will be strong. However, this does not obviate the 
need to consider the role of genetic testing.
A previous review concluded, based on knowl-
edge current at that time, that testing should 
not be offered to those with sporadic ALS.2 An 
increased appreciation of the major limitations of 
family history taken in the clinic, rapid advances in 
preimplantation screening, increasing availability 
of commercial genetic testing and the promise of 
gene-targeted therapy make it timely to reconsider 
this position. This article considers the arguments 
for and against offering routine genetic testing to all 
those with sporadic ALS or FTD.
the genetic landscape of ALs and Ftd
Clinical, pathological and genetic overlap between 
ALS and FTD is now well established.3 Neuronal and 
glial cytoplasmic inclusions containing the 43 kDa 
transactive response DNA binding protein, TDP-43, 
are found in 98% of all cases of ALS and approx-
imately 50% of FTD.4 A hexanucleotide expan-
sion (G4C2) in intron 1 of the C9orf72 gene is the 
cause of chromosome 9-associated5 6 and linked7 8 
pure ALS and FTD (typically the behavioural 
variant), and mixed ALS-FTD,9 10 with multiple 
phenotypes seen within the same pedigree.11 Based 
on meta-analysis of international cohorts (mainly 
Western hemisphere), 5% of those with ALS are 
recorded as familial.12 In FTD, this number is 
higher, at approximately 25%–30%. Approximately 
one-third of ALS and FTD cases will harbour a 
pathogenic C9orf72 expansion. Screening of indi-
viduals with ALS or FTD, but without an apparent 
family history of either, reveals up to 10% as carriers 
of the expansion. While there are about 30 genes in 
which variation has been repeatedly associated with 
ALS, these account collectively for a much smaller 
proportion of cases.13 Fewer genes have been asso-
ciated with FTD, but mutations in GRN and MAPT 
are common causes, although less frequent than 
C9orf72 expansions. Although both ALS and FTD 
are typically disorders of middle-to-late life, some 
genes, for example FUS, have been associated with 
juvenile forms14 (see figure 1).
the clinical distinction between familial and 
sporadic disease is unreliable
The distinction between familial and sporadic 
disease can be influenced by ascertainment bias, and 
there is a growing appreciation of the limitations of 
family history taking in the clinic, compounded by a 
lack of a uniform definition of familial disease.15 16 
Boundaries will also widen significantly with the 
inclusion of related disorders (including autism, 
schizophrenia, bipolar disease, multiple sclerosis 
and Parkinson’s disease17). A reliable family history 
of cognitive disorders is another challenging area, 
specifically differentiating Alzheimer’s disease from 
FTD in relatives based on clinical history alone, 
with a risk of inflating or underestimating the 
frequency of a positive family history.
A single gene variation may result in different 
phenotypes, which may reduce ascertainment if 
the alternative phenotypes are not recognised as 
relevant. C9orf72 expansions have been associated 
with diagnoses of dementia (including behavioural 
variant FTD, primary progressive aphasia and 
even Alzheimer-type dementia), ataxia, chorea and 
schizophrenia. Such disorders may well be over-
looked by respondents when asked about their 
family history in the context of an ALS assessment. 
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The penetrance of many ALS genes is age-dependent and incom-
plete, and family size directly influences the probability of an 
affected relative.18
The distinction between familial and sporadic ALS is there-
fore not clear-cut, and this is underscored by the observation 
that every established familial ALS gene has also been implicated 
in sporadic ALS.19 Penetrance, the probability of manifesting a 
phenotype given one is a carrier of the risk genotype, is closely 
related to the frequency and effect size of disease-associated gene 
variants. Genotypes associated with high penetrance typically 
have very large effect sizes and are usually rare. Low penetrance 
genotypes are usually associated with a small effect. For several 
ALS genes, including the C9orf72 expansion mutation, pene-
trance has been reported as high within affected families,11 20 
but this is not what is expected from observation of the ratio 
of familial and sporadic frequencies in the UK,21 which predicts 
an overall penetrance of 38% (http:// alsod. iop. kcl. ac. uk/ misc/ 
penetrance. aspx), nor from the very strong genetic association 
signal in large studies of people with apparently sporadic ALS.22 
Incomplete penetrance, and the current lack of a gold standard 
for how to measure it, complicates decisions of whether to test 
in the absence of a family history and how to interpret a positive 
result. A further complexity is the rare occurrence of de novo 
mutations, which has been described in FUS14 and SOD1.23
the argument against routinely offering C9orf72 testing
At present, there is no disease-modifying or neuroprotective 
therapy for C9orf72-related disease, and uncertainty remains 
over factors influencing penetrance, which may vary between 
individual families. Consent to test cannot be truly informed 
if there is insufficient information. Although clinical trials are 
underway, until an effective therapy is available, a positive test 
for the C9orf72 expansion in someone with no family history of 
ALS or FTD has life-changing implications for relatives. There 
is therefore understandable concern that cannot yet be offset 
by the prospect of an effective treatment. There will be conse-
quent pressure for consideration of presymptomatic testing, the 
counselling for which requires high-quality evidence. Individuals 
might be strongly advised to involve other family members in 
their decision to undergo testing, but there is a risk that a healthy 
individual’s right not to know about their own risk might be 
inadvertently breached. Uncertainty is compounded by the diffi-
culty in interpretation of a positive gene test in the absence of 
a relevant family history, since there will have been many obli-
gate carriers who did not manifest disease or who developed a 
different but related condition.
the argument for offering C9orf72 testing routinely
It is now possible for at least 10% of all those diagnosed with 
ALS and FTD to understand the cause of their disease, and to 
share this knowledge with relatives to allow them to make deci-
sions about learning their own and any future children’s genetic 
status. For the symptomatic individual, it can bring a degree 
of understanding and accommodation to what is otherwise a 
random and unexplained blow.
For the newly diagnosed individual, a clinician may be tempted 
to withhold information or defer testing because knowledge 
is incomplete, or through concern that the individual or their 
Figure 1 Upper panel: Comparison of proportions of monogenic causes of ALS in those reporting a family history of ALS versus apparently sporadic 
cases. Lower panel: Comparison of proportions of monogenic causes of FTD in those reporting a family history of dementia versus apparently sporadic 
cases. ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia.
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family will be further burdened in the absence of a therapy. In 
many countries, there are no longer healthcare system barriers 
to accessing personal genetic testing, and the provision of impar-
tial and evidence-based information by experienced clinicians is 
preferable to individuals seeking information in an unguided, 
unfiltered way through the internet.
Newly diagnosed individuals may not wish to burden their 
children with worries over the future, but might equally be keen 
to offer them the option to consider preimplantation screening, 
especially in circumstances where it could be undertaken without 
disclosing the presence of an obligate carrier.
Finally, established international research consortia such as the 
Presymptomatic Neurodegeneration Initiative and Genetic Fron-
totemporal Dementia Initiative anticipate exciting new thera-
peutic options. For example, antisense oligonucleotide therapy 
against wild-type SOD1 is about to enter its first trials in ALS, 
and similar therapies for C9orf72 expansions are likely in the 
next few years. Information about anticipated developments that 
are directly relevant to known mutations may be a compelling 
part of the decision-making regarding genetic testing for some 
newly diagnosed individuals.
The imminent availability of therapy has also been identified 
as a major factor in changing physician practice in relation to 
routine testing,23 although benefit from genetic therapy in estab-
lished neurodegenerative disorders remains unproven, and the 
demonstration of efficacy in disease prevention is likely to be 
years away.
It is noteworthy that a survey of 167 clinicians from 21 
different countries (the majority of whom identified themselves 
as having a specialist interest in ALS) revealed that more than 
half would seek genetic testing if they had personally received 
the diagnosis.24 However, it must also be noted that there are 
practical issues in relation to the clinical expertise needed to 
provide nuanced and tailored conversations with individuals 
from diverse backgrounds and to ensuring that resources are 
equally available to all and understandable across a range of 
educations and backgrounds. There are also issues in relation to 
the financial cost to the individual of any testing. Importantly, 
many neurologists lack the specialised training of clinical genet-
icists. Familiarity with the complex issues involved and knowl-
edge of who to refer to specialist services is therefore vital for 
specialists and trainees25 to fully realise the benefits of the rapid 
genetic advances for all those diagnosed with ALS and FTD, and 
their families.
concLusIons
Across the clinical neurosciences, there is increased under-
standing of the need to provide expert interpretation of freely 
available scientific knowledge. It is incumbent on the medical 
profession to recognise patient autonomy and to support deci-
sion-making by those who strongly believe that they are maxi-
mising options for their own children and wider family, as well 
as trying to understand their own disease, while also recognising 
the right not to know one’s genetic status.26 Either way, the prac-
tice of refraining from any discussion of genetic testing should 
now be challenged as an unnecessary limitation to the provision 
of best care in ALS and FTD.
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